You have to login first.
Active hexose correlated compound (AHCC®) is a natural compound extracted from shiitake mushrooms. It was developed in Japan in 1989, and has since been used to improve the immunity of over 100,000 patients, and has been studied in over 50 human clinical trials. AHCC® has the unique ability to stimulate the immune system, which is important in controlling inflammation and infection and regulating healthy cell growth.
AHCC® is used alongside chemotherapy treatments in many Japanese hospitals for its immune supportive effects. The majority of studies have shown reduced side effects, increased quality of life and improved survival rates. Patients taking AHCC® reported less nausea, vomiting and hair loss, and AHCC® improved their body weight and appetite during chemotherapy. The immune effects of AHCC® are not limited to cancer patients and have been applied to microbial infections as well. AOR’s AHCC® is a powerful, evidence based option for people that want to support their immune function, combat stubborn infections and for patients undergoing certain types of chemotherapy.
AHCC® provides antioxidants. The active ingredients of AHCC® include acetylated alpha and beta glucans and saccharides of low molecular weight (5 kDaltons) for optimal bioavailability.
|Serving Size: 1 Capsule||Amount||% Daily|
|AHCC® Proprietary Blend shiitake mycelium extract||500 mg|
alpha-cyclodextrin, dextrin, microcrystalline cellulose, candelilla wax, sodium stearyl fumarate. Capsule: hypromellose.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by products.
Take 1-2 capsules one to three times daily preferably without food, or as directed by a qualified health care practitioner.
Do not take if you are pregnant or breastfeeding. Nausea and diarrhea have been known to occur, in which case, discontinue use.
Shiitake mycelium mushroom root extract
Normal cell growth
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
AHCC® is a registered trademark of Amino Up Co., Ltd.
When it comes to health, we all understand the importance of our immune system. Active hexose correlated compound (AHCC®) is an oligosaccharide extracted from mushrooms grown in rice bran. It was developed in Japan in 1989 and it has since been used to improve the immunity of over 100 000 patients. AHCC® has shown promise for severe immunodeficiencies, in infections, to reduce inflammation and to improve the body’s response to stress.
AHCC® and the Immune System
AHCC® is remarkable because it has the ability to stimulate the immune system. Oral supplementation with AHCC® increases the production by immune cells of at least two protein messengers. These proteins promote the production of macrophages, T cells and natural killer (NK) cells. Immune cells are important for health in general but are specifically involved with the control of infection.
AHCC® and Immunodeficiency
Through its influence on the immune system, AHCC® may help preserve immunity in those whose defense system is slowly being infiltrated by viruses. Preliminary trials with AHCC® have given encouraging results in certain life threatening viral infections.
AHCC® and Infection
Infections are caused by the invasion and the multiplication of microorganisms in the body. We carry 500 to 1000 different species of bacteria throughout our body. Adequate immunity is therefore crucial in preventing infection. Several experiments confirmed AHCC®’s competence for the control of infections.
AHCC® and the Liver
An excess of toxins can damage the liver. Trials have demonstrated that AHCC® protects the liver and improves hepatic function.
AHCC® and Inflammation
It was reported that patients taking AHCC® to prevent the recurrence of abnormal growths had significant improvements in rheumatoid arthritis. AHCC® was also effective at diminishing inflammation in animal studies. It is thought that AHCC® reduces inflammation by modulating the immune system and by improving fat metabolism.
AHCC® and Other Health Conditions
Some studies have shown that AHCC® promoted healthy blood sugar balance. In addition, AHCC® appears to be an adaptogen and may help relieve stress.
If there was any “magic” mushroom, AHCC® is perhaps the closest thing to it. AHCC® is revered around the world as a powerful antioxidant and immune system modulator. For more information, visit www.ahccresearch.com.
AOR’s AHCC® contains one of the highest doses found on the market with fewest additional ingredients, and is available in two sizes for your convenience.
Ahn GH et al. The Clinical Effectiveness of AHCC® Treatment in Cancer Patients with Progressive or Metastasized Cancers: An Observation of Immune Parameters. AHCC Research Association 8th Symposium, Sapporo, Japan, Aug. 2000
Cotran RS, Kumar V, Collins T. Robbins pathologic basis of disease. 6th ed. Toronto: W.B. Saunders Company. 1999.
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004 Aug;21(2):137-48.
Hosokawa M. Combination of AHCC® and Chemotherapy. Anti-Cancer Drugs, 9, 343-350, 1998
Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000 Nov 25;356(9244):1795-9.
Ishibashi H, et al. Prophylactic Efficacy of a Basidiomycetes Preparation AHCC® against Lethal Opportunistic Infections in Mice. Yakugaku Zasshi, 120(8),715-719. 2000
Ishiguro A. Anti-Carcinogenic Activity of AHCC® and PMP. The 2nd Annual Meeting of the Japanese Society for Alternative Medicine & Treatment. Oct. 1999.
Katsuaki Uno, Kenichi Kosuna, Bxiang Sun, Hajimi Fujii, Koji Wakame, Shizuko Chikumaru, George Hosokawa, Yuji Ueda. Active Hexose Correlated Compound (AHCC®) Improves Immunological Parameters and Performance Status of Patients with Solid Tumors. Biotherapy 2000; 14(3):303-309
Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon A-H and Kamiyama Y. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. Journal of Hepatology 2002;37(1):78-86.
Matsushita K. et al., Combination therapy of active hexose correlated compound (AHCC®) plus UFT significantly reduces the metastasis of rat mammary carcinoma, Anti-Cancer Drugs, 343-350, Sep 1998.
Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther. 2004 Dec;3(4):310-22.
Reuters. Report: More than half of U.S. cancer deaths could be prevented-Lifestyle changes would eliminate majority of cases. Washington. March 31, 2005
Rosenberg ES, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523 – 526 (28 September 2000)
Sun B, Wakame K, Mukoda T, Toyoshima A, Kanazawa and Kosuna K. Preventive Effect of AHCC® on Carbon Tetrachloride Induced Liver Injury in Mice. Natural Medicine 51(4), 310-315. 1997
Uno K, Chikumaru S, Hosokawa T. Cancer immunotherapy by a phyto-polysaccharide (AHCC®): its effects and strategy. AHCC Research Association 8th Symposium, Sapporo, Japan, Aug. 2000
Wakame K. Protective Effects of Active Hexose Correlated Compound (AHCC®) on the Onset of Diabetes Induced by Streptozotocin in the Rat. Biomedical Research 20 (3) 145-152. 1999
Wang S et al. Preventive Effects of Active Hexose Correlated Compound (AHCC®) on Oxidative Stress Induced by Ferric Nitrilotriacetate in the Rat. Dokkyo Journal of Medical Sciences 28(2-3). 745-752. 2001
Immunological effect of active hexose correlated compound (AHCC®) in healthy volunteers: a double-blind, placebo-controlled trial.
Nutr Cancer. 2008; 60(5):643-51.
Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y.
The aim of this study was to evaluate the effects of active hexose correlated compound (AHCC®) intake on immune responses by investigating the number and function of circulating dendritic cells (DCs) in healthy volunteers. Twenty-one healthy volunteers were randomized to receive placebo orAHCC at 3.0 g/day for 4 wk. The number of circulating cluster of differentiation (CD)11c( ) DCs (DC1) and CD11c(-) DCs (DC2) were measured. Allogeneic mixed-leukocyte reaction (MLR) was performed. Natural killer (NK) cell activity and the proliferative response of T lymphocytes toward mitogen (phytohemagglutinin [PHA]) were measured. We also measured cytokine production stimulated by lipopolysaccharide [interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, tumor necrosis factor-alpha). The AHCC® group (n = 10) after AHCC® intake had a significantly higher number of total DCs compared to that at baseline and values from control subjects (n = 11). The number of DC1s in the AHCC® group after intake was significantly higher than at baseline. DC2s in the AHCC® group were significantly increased in comparison with controls. The MLR in the AHCC® group was significantly increased compared to controls. No significant differences in PHA, NK cell activity, and cytokine production were found between groups. AHCC® intake resulted in the increased number of DCs and function of DC1s, which have a role in specific immunity.
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC®, in healthy volunteers.
J Nutr Sci Vitaminol (Tokyo). 2007 Dec;53(6):536-9.
Spierings EL, Fujii H, Sun B, Walshe T.
Active Hexose Correlated Compound (AHCC®) is an extract of Lentinula edodes of the basidiomycete family of fungi rich in alpha glucans. AHCC® has been used for many years as a dietary supplement to enhance the immune system and in clinical trials as an adjunctive treatment in Hepatocellular cancer. This multiple dose, Phase I trial, using FDA guidelines, directly investigates the clinical safety and tolerability of AHCC® in healthy subjects. Its safety has been based previously on anecdotal reports and its use in clinical practice. Twenty-six healthy male or female subjects between the ages of 18 and 61 were recruited from the community and gave their consent to participate in the trial. The subjects were given 9 g of AHCC® (150 mL of the currently available liquid AHCC®) PO daily for 14 d. Laboratory data was obtained at baseline and after 14 d of exposure to AHCC® and adverse events were monitored by a non-directed review of systems questionnaire three times during the trial. At each visit the vital signs and adverse events were recorded. Two subjects (7%) dropped out because of nausea and intolerance of the liquid. Adverse effects of nausea, diarrhea, bloating, headache, fatigue, and foot cramps occurred in a total of 6 subjects (20%) but were mild and transient. There were no laboratory abnormalities. When used in high dose in healthy subjects, AHCC® causes no significant abnormality in laboratory parameters. The adverse effects of 9 g of liquid AHCC® per day, a higher dose than used in routine clinical applications, are minimal and the dose was tolerated by 85% of the subjects.
All rights Reserved. Copyright © by AOR 2019